Development of oxoisoaporphine derivatives with topoisomerase I inhibition and reversal of multidrug resistance in breast cancer MCF-7/ADR cells
作者:Hui Zhong、Mingxuan Zhao、Chunyu Wu、Jiayao Zhang、Li Chen、Jianbo Sun
DOI:10.1016/j.ejmech.2022.114300
日期:2022.5
oxoisoaporphine derivatives with topoisomerase I inhibition and cytotoxic activities. Among them, compound 14 showed the most potent cytotoxic activity against all cancer cell lines tested, and substantially lower cytotoxicity to LO2 cells. Molecular docking studies, dynamics simulation and a follow-up enzyme inhibition assay indicated that 14 could interfere with DNA and significantly inhibit the activity of topoisomerase
一系列具有拓扑异构酶 I 抑制和细胞毒活性的氧代异阿朴啡衍生物。其中,化合物14对所有测试的癌细胞系显示出最有效的细胞毒活性,并且对 LO2 细胞的细胞毒性显着降低。分子对接研究、动力学模拟和后续酶抑制试验表明,14可以干扰DNA并显着抑制拓扑异构酶I的活性。进一步的机理研究表明,14可以将细胞周期阻滞在G1期,最终杀死MCF- 7个细胞通过凋亡。此外,14对多药耐药的 MCF-7/ADR 乳腺癌细胞表现出显着的化学逆转能力。其部分机制可能与抑制 MCF-7/ADR P-gp 介导的罗丹明 (Rh123) 外排功能和表达水平,以及抑制 ROS、增加 MCF7/ADR 细胞中 ADR 积累和增强ADR 诱导 MCF7/ADR 细胞凋亡。由于14几乎没有毒副作用,它可能具有进一步研究的潜力。